CorMedix Inc. — Q1 2024 Form 10-Q Summary
Business context and reporting period
Unaudited results cover the three months ended March 31, 2024. CorMedix is a biopharmaceutical company focused on commercializing DefenCath, its FDA-approved catheter-lock product for reducing catheter-related bloodstream infections in certain adult hemodialysis patients. The company had not begun commercial sales by quarter-end; it announced U.S. inpatient availability on April 15, 2024.
Financial performance and position
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Revenue | $0 | $0 |
| Cost of revenues / gross loss | $819,000 cost; $819,000 gross loss | No cost of revenues |
| Research and development | $837,000 | $3.408 million; down 75% |
| Selling, general and administrative | $15.048 million | $7.610 million; up 97% |
| Operating loss | $16.704 million | $11.017 million; loss increased 52% |
| Net loss | $14.466 million | $10.567 million; loss increased 37% |
| Basic and diluted loss per share | $0.25 | $0.24 |
| Net cash used in operating activities | $17.310 million | $10.394 million |
Interest income was $857,000, up from $446,000. A $1.395 million benefit from selling New Jersey net operating losses contributed to the quarter’s tax benefit. The company reported comprehensive loss of $14.477 million.
At March 31, cash and cash equivalents were $35.181 million and short-term investments were $23.371 million; together these totaled $58.552 million, excluding $179,000 of restricted cash. Total assets were $68.024 million and stockholders’ equity was $58.013 million. No conventional borrowings are reported in the provided filing text; reported obligations include $632,000 in operating lease liabilities and a $2.000 million license-agreement payable. The company also reported $21.292 million of preferred-stock liquidation preference.
Changes and notable items
- SG&A increased mainly due to hiring commercial, medical-affairs and marketing personnel, as well as launch preparation. Management said some activities previously classified as R&D shifted to SG&A after FDA approval.
- R&D fell following DefenCath approval; some manufacturing costs are now capitalized as inventory rather than expensed. The company reported $2.320 million of inventory, including $425,000 of finished goods.
- Q1 operating cash use increased by $6.916 million year over year, with lower accrued expenses and accounts payable and higher prepaid expenses also affecting cash flow.
- Cash, cash equivalents and short-term investments declined from $76.031 million at December 31, 2023 to $58.552 million at March 31, 2024. The filing attributes investing cash inflows principally to maturities of short-term investments.
- The company recorded a $2.000 million license intangible asset and matching liability after determining that future net-sales milestones under its ND Partners agreement were probable. Amortization was to begin in Q2 2024 as cost of revenues.
Outlook, risks and contingencies
Management estimates existing cash, cash equivalents and short-term investments will fund operations for at least 12 months from the filing’s issuance, based on assumptions including the timing and uptake of DefenCath’s launch. The company expects continuing operating cash deficits absent significant product revenue and says additional financing may be needed. It had approximately $104.4 million available under its shelf registration statement; future equity financing could dilute shareholders, while debt or partnerships may carry restrictions or require relinquishing rights. The filing provides no numerical sales or earnings guidance.
Commercial developments reported after quarter-end include CMS approval of TDAPA reimbursement effective July 1, 2024, publication of a new HCPCS code, and a five-year supply contract with ARC Dialysis. CorMedix also submitted an FDA supplement to add Siegfried Hameln as an alternate finished-dosage manufacturing site and anticipated a decision by year-end. CMS had indicated it would not revise the inpatient add-on payment to reflect the lower actual product price until the October 2024 review cycle.
Key risks include dependence on successful DefenCath commercialization and reimbursement, expected concentration of more than 70% of outpatient market volume among two large dialysis providers, and reliance on single FDA-approved suppliers for each key active ingredient and one approved finished-dosage site. The company is working to qualify alternatives. A required pediatric study remains outstanding, with FDA discussions expected in 2024.
The securities class action remains pending; an amended complaint was filed April 22, 2024, and the company says it intends to contest the claims. Related derivative litigation is stayed. The filing reports no material changes to previously disclosed risk factors.
Important facts for investors to verify
- Whether DefenCath achieves commercial adoption and reimbursed use, particularly in outpatient dialysis following TDAPA implementation.
- Actual launch revenue, product margins and cash burn compared with management’s assumptions and the stated at-least-12-month liquidity estimate.
- Progress qualifying alternative API suppliers and the additional finished-dosage manufacturing site.
- CMS’s future inpatient payment adjustment and the effect of pricing and reimbursement on demand.
- Potential financial or operational effects of the securities litigation, license milestones and required pediatric study.